Dr Raffaele Baffa, Chief Medical Officer of CARsgen, commented that, “Gastric cancer is a devastating disease that affects over a million people worldwide. Despite advances in treatment, the prognosis for patients with advanced gastric cancer remains poor, highlighting the urgent need for new and innovative therapies. CT041 has shown promising results in previous trials, demonstrating clinical efficacy and a manageable safety profile. We believe that CT041 has the potential to become an effective treatment option for patients with advanced gastric cancer. We would also like to express our gratitude to the patients, investigators, and our dedicated team at CARsgen for their commitment to advancing the field of cancer immunotherapy. We look forward to sharing updates on our clinical progress as we continue to work towards our goal of developing innovative CAR T-cell therapies for patients.”
